TORONTO, Nov. 10, 2015 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for a generic version of PrAvelox® for the treatment of adults with respiratory tract infections, including acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis and community acquired pneumonia of mild to moderate severity.
In Canada, PrAvelox® had annual sales of approximately $28.4 million based on IMS Brogan sales data as of September 2015. PrTeva-Moxifloxacin is available immediately in pharmacies across Canada.
"As cold and flu season is just beginning, we are proud to have played our part in expediting the availability of a more affordable version of this physician and pharmacist trusted medication for respiratory tract infections," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "We do, however, know that the health risk related to antimicrobial resistance is a real concern and we support the work conducted by the Public Health Agency of Canada and their Federal Framework for Action, aiming to actively protect Canadians.[i]"
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,000[ii] prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400[iii] products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.
| [i] |
Public Health Agency of Canada. Antimicrobial Resistance and Use in Canada: A Federal Framework for Action. http://healthycanadians.gc.ca/alt/pdf/drugs-products-medicaments-produits/buying-using-achat-utilisation/antibiotic-resistance-antibiotique/antimicrobial-framework-cadre-antimicrobiens-eng.pdf . Accessed October 2015. |
| [ii] |
IMS Compuscript TRx MAT September 2015 |
| [iii] |
IMS CD&H MAT September 2015 |
SOURCE Teva Canada Limited
PR Contact: Teva Pharmaceutical Industries Ltd., Denise Bradley, Sr. Vice President, Global Corporate Reputation, Teva Pharmaceuticals, p. +1.215.591.8974, [email protected]
Share this article